Customers of ZOA Energy, the energy drink brand co-founded by Dwayne “The Rock” Johnson, may be eligible for cash payouts ...
Arcutis aims to expand its market reach with new approvals. Management recently pleased the market with its sales guidance for Zoryve. Shares in Arcutis Biotherapeutics (NASDAQ: ARQT) continued their ...
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in ...
Zoryve cream 0.05% is available in a 60g tube. Zoryve ® (roflumilast) cream 0.05% is now available for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can ...
Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback